Catalyst Pharmaceuticals' Agamree matches Emflaza's glucocorticoid activity while showing less immun

PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher th

WARREN, N.J., June 17, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced th

PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes

– Refinancing transaction with proceeds to be utilized to repurchase or repay the 2026 convertible n

PTC intends to grant the initial purchasers an option to purchase, within a 13-day period beginning

– Proceeds to be used to repurchase or repay 2026 convertible notes prior to or at maturity – – Offe

PTC Therapeutics, Inc. (PTCT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 202

Jefferies analyst Faisal Khurshid upgrades PTC Therapeutics (NASDAQ:PTCT) from Hold to Buy and ra

PTC Therapeutics, Inc. (PTCT) Presents at Bank of America Global Healthcare Conference 2026 Transcri

PTC Therapeutics is transitioning from a legacy rare disease business to a growth-focused model, anc

PTC Therapeutics NASDAQ: PTCT reported a record first quarter for product revenue and raised its 202

TD Cowen analyst Joseph Thome upgrades PTC Therapeutics (NASDAQ:PTCT) from Hold to Buy and raises

RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:PTCT) with a Sector Perform

Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight a

PTC Therapeutics, Inc. (PTCT) Q1 2026 Earnings Call Transcript

While the top- and bottom-line numbers for PTC Therapeutics (PTCT) give a sense of how the business

PTC Therapeutics (PTCT) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus

PTC Therapeutics (NASDAQ:PTCT) raises FY2026 sales outlook from $700.000 million-$800.000 million to

PTC Therapeutics (NASDAQ:PTCT) reported quarterly losses of $(0.03) per share which beat the analyst

– First quarter 2026 total revenue of $273 million, including $226 million of product revenue, suppo

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for PTC Therapeutics (PTCT), del

WARREN, N.J., May 4, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that

PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earn

PTC Therapeutics, Inc. (PTCT) Discusses 24-Month Interim Results of PIVOT-HD Long-Term Extension Stu

PTC Therapeutics Inc. (NASDAQ:PTCT) shares are tumbling on Wednesday, after the company reported top

PTC Therapeutics stock drops after PIVOT-HD update, as FDA approval doubts offset dose-based benefit

- Dose-dependent benefit on cUHDRS in Stage 2 participants compared to matched natural history cohor

- Dose-dependent benefit on cUHDRS in Stage 2 participants compared to matched natural history cohor

Jefferies analyst Faisal Khurshid downgrades PTC Therapeutics (NASDAQ:PTCT) from Buy to Hold and

Morgan Stanley analyst Jeffrey Hung maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight an

Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight a

RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:PTCT) with a Sector Perform

B of A Securities analyst Tazeen Ahmad maintains PTC Therapeutics (NASDAQ:PTCT) with a Buy and lo

PTC Therapeutics (NASDAQ:PTCT) sees FY2026 sales of $700.000 million-$800.000 million vs $959.579 mi

PTC Therapeutics (NASDAQ:PTCT) reported quarterly losses of $(1.67) per share which missed the analy

PTC Therapeutics, Inc. (PTCT) stock closed lower following the withdrawal of its New Drug Applicatio

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it has withdrawn the New Drug Application

Barclays analyst Eliana Merle upgrades PTC Therapeutics (NASDAQ:PTCT) from Equal-Weight to Overwe

Royalty Pharma has acquired PTC's remaining royalty on Roche's Evrysdi for $240 million upfr

PTC will now engage in pricing discussions which are expected to conclude in Q1 2026, with launch oc

- Broad label includes all age groups and full range of PKU subtypes -TORONTO, Dec. 10, 2025 /CNW/ -

RBC Capital analyst Brian Abrahams downgrades PTC Therapeutics (NASDAQ:PTCT) from Outperform to S

Sandisk is joining the S&P 500 Index, prompting a boost in the share price Monday after market c

https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20251124-1480959/1480959_ipg-pin